Current Oncology Reports

, Volume 15, Issue 2, pp 182–189

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

  • Thierry Conroy
  • Céline Gavoille
  • Emmanuelle Samalin
  • Marc Ychou
  • Michel Ducreux
Gastrointestinal Cancers (BG Czito, Section Editor)

DOI: 10.1007/s11912-012-0290-4

Cite this article as:
Conroy, T., Gavoille, C., Samalin, E. et al. Curr Oncol Rep (2013) 15: 182. doi:10.1007/s11912-012-0290-4

Abstract

In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer.

Keywords

Pancreatic cancerChemotherapyOxaliplatinIrinotecan

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Thierry Conroy
    • 1
    • 2
  • Céline Gavoille
    • 2
  • Emmanuelle Samalin
    • 3
  • Marc Ychou
    • 3
  • Michel Ducreux
    • 4
  1. 1.EA 4360 and Department of Medical Oncology, Centre Alexis VautrinUniversité de LorraineVandoeuvre-lès-Nancy CedexFrance
  2. 2.Department of Medical OncologyCentre Alexis VautrinVandoeuvre-lès-Nancy CedexFrance
  3. 3.Department of Medical OncologyCentre Val d’AurelleMontpellier Cedex 5France
  4. 4.Department of MedicineInstitut Gustave RoussyVillejuif CedexFrance